{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:33:53Z","timestamp":1773729233959,"version":"3.50.1"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,3,2]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised, methotrexate (MTX)-controlled trials in conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)\/biologic (bDMARD)-na\u00efve RA patients using matching-adjusted indirect comparisons (MAICs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were from Phase III trials on patients receiving monotherapy baricitinib, tocilizumab, adalimumab, tofacitinib or MTX. Pain was assessed using a visual analogue scale (0\u2013100 mm) and physical function using the Health Assessment Questionnaire-Disability Index (HAQ-DI). An MAIC based on treatment-arm matching, an MAIC with study-level matching and Bucher\u2019s method without matching compared change in outcomes between therapies. Matching variables included age, gender, baseline disease activity and baseline value of outcome measure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>With all methods, greater improvements were observed in pain and HAQ-DI at 6 months for baricitinib compared with adalimumab and tocilizumab (<jats:italic>p<\/jats:italic>&lt;0.05). Differences in treatment effects (TEs) favouring baricitinib for pain VAS for treatment-arm matching, study-level matching and Bucher\u2019s method, respectively, were \u221212, \u221212 and \u221212 for baricitinib versus adalimumab and \u22127, \u22127 and \u22129 for baricitinib versus tocilizumab; the difference in TEs for HAQ-DI was \u22120.28, \u22120.28 and \u22120.30 for adalimumab and \u22120.23, \u22120.23 and \u22120.26 for tocilizumab. For baricitinib versus tofacitinib, no statistically significant differences for pain improvement were observed except with one of the three methods (Bucher method) and none for HAQ-DI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Results suggest greater pain reduction and improved physical function for baricitinib monotherapy compared with tocilizumab and adalimumab monotherapy. No statistically significant differences in pain reduction and improved physical function were observed between baricitinib and tofacitinib with the MAIC analyses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001131","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T10:41:22Z","timestamp":1588675282000},"page":"e001131","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are na\u00efve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01711359","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00109408","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01007435","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01039688","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00195663","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"B","family":"Fautrel","sequence":"first","affiliation":[{"name":"Sorbonne University, Pierre Louis Institute for Epidemiology and Public Health; Assistance Publique Hopitaux de Paris, Pitie-Salpetriere University Hospital, Rheumatology Dept, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P C","family":"Taylor","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, Univ of Oxford, Headington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"van de Laar","sequence":"additional","affiliation":[{"name":"University of Twente and Arthritis Center Twente, Enschede, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Emery","sequence":"additional","affiliation":[{"name":"Leeds MSK Biomed\/Chapel Allerton Hosp, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"De Leonardis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C L","family":"Kannowski","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Kadziola","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"De La Torre","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Med Ctr, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2025090312432751000_6.1.e001131.1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00296-018-4005-5","article-title":"Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis","volume":"38","author":"Fautrel","year":"2018","journal-title":"Rheumatol Int"},{"key":"2025090312432751000_6.1.e001131.2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","article-title":"A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective","volume":"36","author":"Taylor","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025090312432751000_6.1.e001131.3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/annrheumdis-2018-eular.5337","article-title":"Op0329-hpr\u2005outcomes that matter to people living with inflammatory arthritis; a global standard set, developed by the international consortium for health outcome measurement (ichom) working group for inflammatory arthritis","volume":"77","author":"Oude Voshaar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312432751000_6.1.e001131.4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312432751000_6.1.e001131.5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"2025090312432751000_6.1.e001131.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"2025090312432751000_6.1.e001131.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101161"},{"key":"2025090312432751000_6.1.e001131.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207628"},{"key":"2025090312432751000_6.1.e001131.9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312432751000_6.1.e001131.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"2025090312432751000_6.1.e001131.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312432751000_6.1.e001131.12","first-page":"S14","article-title":"The health assessment questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312432751000_6.1.e001131.13","unstructured":"Ramey D , Fries J , Singh G . The health assessment questionnaire 1995- status and review. In: Spilker B , ed. Pharmacoeconomics and quality of life in clinical trials . Philadelphia, Lippincott-Raven, 1996: 227\u201337."},{"key":"2025090312432751000_6.1.e001131.14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jval.2018.06.018","article-title":"Alternative weighting approaches for anchored matching-adjusted indirect comparisons via a common comparator","volume":"22","author":"Petto","year":"2019","journal-title":"Value Health"},{"key":"2025090312432751000_6.1.e001131.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"2025090312432751000_6.1.e001131.16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF03261873","article-title":"Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder: application of a matching-adjusted indirect comparison","volume":"10","author":"Erder","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"key":"2025090312432751000_6.1.e001131.17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40263-013-0102-x","article-title":"Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology","volume":"27","author":"Sikirica","year":"2013","journal-title":"CNS Drugs"},{"key":"2025090312432751000_6.1.e001131.18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/cer-2018-0141","article-title":"Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis","volume":"8","author":"Strand","year":"2019","journal-title":"J Comp Eff Res"},{"key":"2025090312432751000_6.1.e001131.19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-018-0106-6","article-title":"Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2025090312432751000_6.1.e001131.20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40744-017-0070-6","article-title":"Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2025090312432751000_6.1.e001131.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:43:36Z","timestamp":1756928616000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,5]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/rmdopen-2019-001131"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001131","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}